Search results
Results from the WOW.Com Content Network
Research regarding late-life depression often focuses on late-onset depression, which is defined as a major depressive episode occurring for the first time in an older person (various sources define this threshold differently, typically within the range of 60–65 years old). [1] [2]
Reference ranges (reference intervals) for blood tests are sets of values used by a health professional to interpret a set of medical test results from blood samples. Reference ranges for blood tests are studied within the field of clinical chemistry (also known as "clinical biochemistry", "chemical pathology" or "pure blood chemistry"), the ...
This supports why mortality significantly increases with systolic blood pressure below 110 mmHg in older adults but not until 95 mmHg in younger patients. [53] [54] This is why several centers and studies support using older age as a TTA criterion as a means to reduce mortality in this population, regardless of the mechanism of injury. [55]
Individuals with depression often describe a slowing of thought, an inability to concentrate and make decisions, and being easily distracted. [3] In the elderly, the decreased concentration caused by a major depressive episode may present as deficits in memory. [3] This is referred to as pseudodementia and often goes away with treatment. [3]
Basic blood biochemistry and cell counts can also be used to accurately predict the chronological age. [7] Further studies of the hematological clock on the large datasets from South Korean, Canadian, and Eastern European populations demonstrated that biomarkers of aging may be population-specific and predictive of mortality. [ 8 ]
In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues [ 1 ] to examine normal biological processes , pathogenic processes, or pharmacologic responses to a therapeutic intervention . [ 2 ]
“The event or death may have been related to the underlying disease being treated, may have been caused by some other product being used at the same time, or may have occurred for other reasons.” The Times story also cited a buprenorphine study by researchers in Sweden that looked at “100 autopsies where buprenorphine had been detected.”
Brain failure after clinical death is now known to be due to a complex series of processes called reperfusion injury that occur after blood circulation has been restored, especially processes that interfere with blood circulation during the recovery period. [11] Control of these processes is the subject of ongoing research.